STOCK TITAN
  1. Home
  2. News
  3. VTGN

VistaGen Therapeutics Inc - VTGN STOCK NEWS

Welcome to our dedicated news page for VistaGen Therapeutics (Ticker: VTGN), a resource for investors and traders seeking the latest updates and insights on VistaGen Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VistaGen Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VistaGen Therapeutics's position in the market.

News
Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
Rhea-AI Summary
Vistagen (VTGN) announces positive results from a Phase 2A pilot study of PH15 nasal spray for improvement of psychomotor impairment caused by mental fatigue. The study demonstrated statistically significant efficacy of PH15 versus placebo and caffeine in sleep-deprived participants. PH15 was safe and well-tolerated, showing potential as an innovative treatment option for enhancing psychomotor performance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
Rhea-AI Summary
Vistagen (Nasdaq: VTGN) announces the presentation of clinical trial data for fasedienol and PH80 at the ADAA Conference. Vistagen will showcase Phase 3 development of fasedienol for social anxiety disorder and Phase 2 study of PH80 for women's health disorders. The company will also receive the ADAA 2024 Partner Recognition Award.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.87%
Tags
conferences
-
News
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
Rhea-AI Summary
Vistagen initiates PALISADE-3 Phase 3 trial for fasedienol in social anxiety disorder, enrolling first patient. PALISADE-3 aims to evaluate efficacy and safety of fasedienol in relieving anxiety symptoms induced by public speaking challenge.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
clinical trial
News
Vistagen to Present at Stifel 2024 Virtual CNS Days
Rhea-AI Summary
Vistagen (VTGN) to participate in Stifel 2024 Virtual CNS Days, presenting groundbreaking therapies for psychiatric and neurological disorders. CEO Shawn Singh to host fireside chat on March 20, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
conferences
-
News
Vistagen to Present at TD Cowen 44th Annual Health Care Conference
Rhea-AI Summary
Vistagen (Nasdaq: VTGN) will present at the TD Cowen 44th Annual Health Care Conference, with CEO Shawn Singh giving a corporate overview on March 6, 2024. Investors can arrange one-on-one meetings through their Cowen representative.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
conferences
-
News
Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update
Rhea-AI Summary
Vistagen reports financial results for Q3 2024 and updates on PALISADE Phase 3 program for social anxiety disorder treatment. Initiates trials for fasedienol and progresses itruvone and PH80 development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
earnings
News
Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024
Rhea-AI Summary
Vistagen (NASDAQ: VTGN) will host a conference call and webcast on February 13, 2024, to report results for its fiscal year 2024 third quarter and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.58%
Tags
conferences earnings
-
News
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain
Rhea-AI Summary
Vistagen (Nasdaq: VTGN) announced positive preclinical and Phase 1 clinical data for AV-101, a potential treatment for neuropathic pain, with a favorable safety profile. The European Patent Office issued a Notice of Intention to Grant a patent related to the use of AV-101 for the treatment of neuropathic pain, adding to Vistagen's global patent portfolio on therapeutic uses and manufacturing techniques for AV-101.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.38%
Tags
none
-
News
Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results
Rhea-AI Summary
Vistagen (Nasdaq: VTGN) reports positive Phase 3 results for fasedienol in the treatment of social anxiety disorder (SAD), with preparations underway for potential NDA-enabling Phase 3 studies in 2024. The company secured $137.7 million in gross proceeds, including $100 million from an underwritten public offering of equity securities, strengthening its financial position for future developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.07%
Tags
earnings
News
Vistagen to Present at Stifel 2023 Healthcare Conference
Rhea-AI Summary
Vistagen (Nasdaq: VTGN) announces participation in Stifel 2023 Healthcare Conference to present corporate overview and host one-on-one meetings, offering webcast accessibility through the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.49%
Tags
conferences
Stock VTGN logo
VistaGen Therapeutics Inc

Nasdaq:VTGN

VTGN Rankings

#4080 Ranked by Market Cap
#3612 Ranked by Stock Gains
N/A Ranked by Dividends

VTGN Stock Data

132.15M
15.25M
0.17%
63.16%
4.73%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
South San Francisco

About VTGN

we have developed a versatile stem cell technology platform based on the controlled differentiation of human pluripotent stem cells into mature, non-transformed, human cells which can be used to create novel bioassay systems for predictive toxicology, drug metabolism screening, drug discovery, drug rescue and cell therapy. we believe our stem cell technology platform, human clinical trials in a test tube™, can provide clinically relevant predictions of potential toxicity and metabolism issues of promising new drug candidates long before they are ever tested in humans.